Ind Swift Laboratories Stock Screener | Share Price & Fundamental Analysis
INDSWFTLAB
Pharmaceuticals
Share Price NSE
₹141.89
▲
4.36 (3.17%)
Share Price BSE
₹141.45
▲
3.95 (2.87%)
Track Ind Swift Laboratories share price live with TickJournal's free stock screener.
Analyze Ind Swift Laboratories share price history trends and compare 52-week high low
levels.
Calculate INDSWFTLAB stock fair value using fundamental analysis and view live share price charts.
Determine Ind Swift Laboratories share intrinsic value and compare it with current INDSWFTLAB share price.
Record your Ind Swift Laboratories trades in TickJournal's free trading journal and track your portfolio performance.
Ind Swift Laboratories Market Cap
₹1,173.08 Cr.
EPS (TTM)
₹37.25
Dividend Yield
-
Debt to Equity
0.11
INDSWFTLAB 52 Week High
₹143.74
Ind Swift Laboratories 52 Week Low
₹88.15
Operating Margin
-1.00%
Profit Margin
5.62%
INDSWFTLAB Revenue (TTM)
₹178.00
EBITDA
₹26.00
Net Income
₹10.00
Total Assets
₹1,438.00
Total Equity
₹1,173.00
Ind Swift Laboratories Share Price History - Stock Screener Chart
Screen INDSWFTLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Ind Swift Laboratories Company Profile - Fundamental Screener
Screen Ind Swift Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for INDSWFTLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE915B01019
Ind Swift Laboratories Balance Sheet Screener
Screen INDSWFTLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,438 | 1,460 | 1,824 | 1,801 | 1,818 | 1,870 | 1,924 | 2,023 | 2,138 | 2,215 |
| Current Assets | 865 | 960 | 1,165 | 1,075 | 944 | 863 | 836 | 842 | 832 | 926 |
| Fixed Assets | 273 | 192 | 588 | 630 | 753 | 843 | 914 | 934 | 1,042 | 1,099 |
| Liabilities | ||||||||||
| Total Liabilities | 1,438 | 1,460 | 1,824 | 1,801 | 1,818 | 1,870 | 1,924 | 2,023 | 2,138 | 2,215 |
| Current Liabilities | 45 | 215 | 771 | 866 | 901 | 906 | 980 | 534 | 601 | 746 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,173 | 812 | 682 | 601 | 603 | 641 | 588 | 553 | 531 | 517 |
| Share Capital | 69 | 67 | 60 | 60 | 60 | 60 | 48 | 46 | 46 | 42 |
| Reserves & Surplus | 1,030 | 745 | 622 | 541 | 544 | 581 | 540 | 507 | 486 | 476 |
Ind Swift Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Ind Swift Laboratories income statement and profit fundamentals.
Analyze INDSWFTLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Ind Swift Laboratories share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 178 | 171 | 167 | 359 | 145 | 25 | 44 | 987 | 295 | 297 | 316 | 315 | 321 | 318 | 288 |
| Expenses | 153 | 151 | 149 | 147 | 136 | 24 | 43 | 437 | 236 | 224 | 250 | 267 | 259 | 252 | 227 |
| EBITDA | 26 | 19 | 18 | 211 | 9 | 1 | 1 | 549 | 59 | 73 | 66 | 47 | 62 | 66 | 60 |
| Operating Profit % | -1.00% | 1.00% | 2.00% | -7.00% | -6.00% | -99.00% | -29.00% | 17.00% | 18.00% | 23.00% | 19.00% | 12.00% | 17.00% | 19.00% | 19.00% |
| Depreciation | 9 | 7 | 7 | 7 | 6 | 0 | 0 | 20 | 14 | 13 | 14 | 9 | 15 | 16 | 16 |
| Interest | 1 | 2 | 1 | -27 | 10 | 0 | 0 | 3 | 21 | 21 | 20 | 22 | 22 | 24 | 24 |
| Profit Before Tax | 16 | 10 | 10 | 231 | -7 | 1 | 1 | 527 | 24 | 39 | 32 | 16 | 24 | 26 | 20 |
| Tax | 7 | 2 | 2 | 8 | -1 | 0 | 0 | 33 | 5 | 7 | 14 | 41 | -3 | 1 | 0 |
| Net Profit | 10 | 8 | 9 | 222 | -6 | 0 | 1 | 494 | 19 | 32 | 17 | -25 | 28 | 25 | 20 |
| EPS | 1.17 | 1.00 | 1.28 | 32.96 | -0.82 | 0.07 | 0.16 | 83.55 | 3.29 | 5.36 | 2.92 | -4.25 | 4.65 | 4.29 | 3.36 |
Ind Swift Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen INDSWFTLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -26 | -187 | 195 | 150 | 135 | 125 | -64 | 73 | 96 | 79 |
| Investing Activities | -110 | -28 | -13 | 5 | -10 | -9 | -13 | -17 | -31 | -29 |
| Financing Activities | 69 | 657 | -186 | -141 | -124 | -133 | 100 | -62 | -69 | -48 |
| Net Cash Flow | -67 | 443 | -4 | 14 | 1 | -17 | 23 | -6 | -4 | 3 |
Ind Swift Laboratories Shareholding Pattern Screener
See Ind Swift Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Ind Swift Laboratories promoter holding and ownership changes for INDSWFTLAB on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Aug | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 40.94% | 40.94% | 36.77% | 39.50% | 39.50% | 39.50% | 42.00% | 42.00% |
| FII Holding | 3.07% | 4.27% | 0.00% | 0.00% | 14.80% | 14.33% | 0.25% | 1.26% |
| DII Holding | 0.91% | 0.91% | 0.00% | 0.00% | 0.68% | 0.68% | 8.03% | 0.94% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 37.61% | 41.36% | 35.11% | 34.75% | 34.96% | 35.06% | 30.46% | 36.69% |
| Other Holding | 17.46% | 12.51% | 28.12% | 25.76% | 10.06% | 10.43% | 19.26% | 19.11% |
| Shareholder Count | 28,190 | 28,709 | 28,539 | 28,892 | 43,780 | 42,121 | 22,439 | 25,461 |
Ind Swift Laboratories Share Dividend Screener - Share Yield Analysis
Check Ind Swift Laboratories dividend history with payout and yield data.
View Ind Swift Laboratories dividend details including ex-dates and amounts for INDSWFTLAB stock.
Ind Swift Laboratories Stock Index Membership
See which indices include Ind Swift Laboratories stock.
Check INDSWFTLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Ind Swift Laboratories Market Events Screener - Corporate Actions
Get Ind Swift Laboratories corporate actions including splits, bonuses, and buybacks.
Check Ind Swift Laboratories stock events that may affect INDSWFTLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 1.99% | ||
| Annual General Meeting | NA | -11.66% | ||
| 2026-01-31 | 2026-01-31 | Quarterly Result Announcement | NA | 6.32% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 1.70% |
| 2025-08-14 | 2025-08-14 | Merger - Demerger | 100:15 | 0.00% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -1.61% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -4.59% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 7.84% |
| 2025-02-22 | 2025-02-22 | Extraordinary General Meeting | NA | -12.26% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -11.42% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | -2.34% |
| 2024-07-22 | 2024-07-22 | Extraordinary General Meeting | NA | 2.49% |
| 2023-10-06 | 2023-10-06 | Extraordinary General Meeting | NA | -12.79% |
Ind Swift Laboratories Competitors Screener - Peer Comparison
Screen INDSWFTLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 408,007 | 37.20 | 54,729 | 9.71% | 10,980 | 53.25 |
| Divis Laboratories | 163,250 | 66.07 | 9,712 | 18.67% | 2,191 | 48.15 |
| Torrent Pharmaceuticals | 144,229 | 64.43 | 11,539 | 6.99% | 1,911 | 70.35 |
| Cipla | 109,566 | 23.71 | 28,410 | 7.12% | 5,291 | 45.95 |
| Dr Reddys Laboratories | 105,948 | 19.16 | 33,741 | 16.73% | 5,725 | 58.53 |
| Lupin | 101,478 | 21.52 | 22,910 | 13.74% | 3,306 | 60.82 |
| Zydus Life Science | 91,613 | 18.12 | 23,511 | 18.55% | 4,615 | 52.96 |
| Mankind Pharma | 86,000 | 47.17 | 12,744 | 20.90% | 2,007 | 45.43 |
| Aurobindo Pharma | 68,802 | 19.14 | 32,346 | 9.43% | 3,484 | 51.95 |
| Alkem Laboratories | 65,528 | 26.80 | 13,458 | 3.70% | 2,216 | 40.44 |
Ind Swift Laboratories Company Announcements - News Screener
Screen INDSWFTLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Press Release / Media Release | View | |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-31 | Statement Of NIL Deviation For The Quarter Ended December 31 2025 | View |
| 2026-01-31 | Financial Results For The Quarter Ended December 31 2025 On Standalone And Consolidated Basis. | View |
| 2026-01-31 | Board Meeting Outcome for Outcome Of The Board Meeting Held On January 31 2026 | View |
| 2026-01-28 | Board Meeting Intimation for Meeting Of The Board Of Directors Scheduled To Be Held On January 31 2026. | View |
| 2026-01-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-14 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-30 | Closure of Trading Window | View |
| 2025-12-18 | Disclosure Under Regulation 10(6)- Report To Stock Exchanges In Respect Of Acquisition Made In Reliance Upon Exemption Provided For In Regulation 10 Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 For Inter-Se Transfer Of Shares | View |
| 2025-12-18 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-15 | Receipt Of Good Manufacturing Practice (GMP) Certificate From National Center For Public Health And Pharmacy (NNGYK-Hungary). | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-05 | Intimation Of Trading Approval Obtained From Stock Exchanges For 8124698 Equity Shares Of ?10/- Each Issued Pursuant To The Approved Scheme Of Amalgamation | View |
| 2025-11-21 | Intimation Regarding Receipt Of ISO 14001:2015 And ISO 45001:2018 Certifications | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2025-11-14 | Board Meeting Outcome for Approval Of Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |